Status:
UNKNOWN
Evaluation of Post-Procedure Administration of Celecoxib Following Shoulder Surgery
Lead Sponsor:
St. Louis Joint Replacement Institute
Conditions:
Reverse or Primary Total Shoulder
Rotator Cuff- Full Thickness- Repair
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Hypothesis It is expected that shoulder surgery patients treated with celecoxib (Celebrex) will experience significantly reduced narcotic use as measured by pill count compared with controls at three ...
Detailed Description
Hypothesis It is expected that shoulder surgery patients treated with celecoxib (Celebrex) will experience significantly reduced narcotic use as measured by pill count compared with controls at three ...
Eligibility Criteria
Inclusion
- Inclusion / Exclusion Criteria for Pfizer Study
- community ambulators
- D/C to home only
- only MO and IL pts
- Primary unilateral shoulder replacements / Cuff tear
- Full Thickness, single tendon tear
Exclusion
- allergy, sensitivity, or inability to take Celebrex
- CR \>1.5
- h/o bleeding ulcers
- h/o Inflammatory bowel disease, Crohn's disease, ulcerative colitis
- Coagulation abnormality
- Coumadin/Plavix/Xaralto
- CHF
- Previous MI or CVA
- Current use of long acting narcotics (Fentanyl Patches, Oxycontin CR, MS Contin)
- Refusal by PCP or cardiologist
Key Trial Info
Start Date :
February 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2018
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03305068
Start Date
February 1 2014
End Date
June 1 2018
Last Update
April 27 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SSM DePaul
Bridgeton, Missouri, United States, 63044